Beyond a scientist: Clay Siegall, Seattle Genetics CEO

Clay Siegall is the president, chief executive officer, and chairman of the board of Seattle Genetics. Siegall studied genetics at George Washington University and zoology at the University of Maryland. Dr. Siegall has won awards such as the University of Maryland Alumnus of the Year and the Pacific Northwest Ernst & Young Entrepreneur of the Year. Although he worked as a scientist for many years, Dr. Siegall has combined his training and further scientific research to make immense progress in the field of cancer therapy. In 2011, the company received FDA approval of ADCETRIS, a revolutionary cancer treatment. Under Dr. Siegall’s guidance, Seattle Genetics has supported licenses of over $300 million and raised $1.2 billion via public and private finances.
Today, he is active on social media and aims to raise cancer awareness and methods for treatment. He has been featured in interviews by CNN and MSNBC, where he promoted his company and informed media outlets about the severity of cancer therapy. Although he is the CEO of Seattle Genetics, Dr. Siegall remains active in the medical community; he is renowned for his outspoken mindset toward remedies and willingness to innovate. Journalists who have published articles about Dr. Siegall note his capacity to intake huge amounts of information and develop effective solutions never seen before. For example, ADCETRIS is a state of the art treatment and Dr. Siegall continues to modify it in his laboratory. Overall, news sources have reported extremely positive experiences. In the 21st century, it is hard to find a scientist/doctor as honest and passionate as Dr. Siegall. In the field of cancer therapy, he is a pioneer that will lead the way for new protocols in years to come.

Posted in CEO